KSPI:NASDAQJoint Stock Company Kaspi.kz - American Depository Shares Analysis
Data as of 2026-05-24 - not real-time
$91.54
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
KSPI is trading at $91.54, comfortably above its 20‑day SMA (87.61) and 50‑day SMA (81.40), with the price sitting near the upper end of its recent range and below the identified resistance at $92.81. The RSI of 65 and a bullish MACD histogram (+0.14) indicate continued upward momentum, while the market’s Fear & Greed Index shows "Extreme Greed," supporting short‑term buying pressure. Valuation metrics are compelling: a trailing P/E of 7.8 is far below the industry average of 39.5, and the forward P/E of 0.013 suggests the market expects rapid earnings expansion. Revenue is growing at a robust 31% year‑over‑year, and EPS guidance has jumped dramatically, reinforcing the growth narrative. The company recently raised $600 million in senior notes, improving liquidity ahead of the Q1 earnings release. However, free cash flow is negative and the dividend payout ratio is zero, raising questions about the long‑term sustainability of the 3.9% yield.
Geopolitical exposure to Kazakhstan, Azerbaijan and Ukraine adds a layer of regulatory and currency risk, while a beta of 1.28 and 30‑day volatility above 40% signal price swings. Despite these headwinds, the stock’s low price‑to‑book (0.008) and strong return on equity (46.7%) suggest it is still undervalued. The consensus EPS estimate for Q1 is $2.65, and analysts maintain a "Buy" consensus, reflecting confidence in the earnings trajectory. Considering the blend of bullish technicals, attractive valuation and growth outlook, the near‑term outlook is positive, but investors should monitor cash flow generation and regional risk factors.
Geopolitical exposure to Kazakhstan, Azerbaijan and Ukraine adds a layer of regulatory and currency risk, while a beta of 1.28 and 30‑day volatility above 40% signal price swings. Despite these headwinds, the stock’s low price‑to‑book (0.008) and strong return on equity (46.7%) suggest it is still undervalued. The consensus EPS estimate for Q1 is $2.65, and analysts maintain a "Buy" consensus, reflecting confidence in the earnings trajectory. Considering the blend of bullish technicals, attractive valuation and growth outlook, the near‑term outlook is positive, but investors should monitor cash flow generation and regional risk factors.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 8/10
Key Factors
- Bullish technical indicators (price above SMA, RSI 65, MACD bullish)
- Support level well below current price and positive market sentiment
- Upcoming earnings release with consensus EPS beat expectations
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Strong revenue growth (~31%) and low trailing P/E versus peers
- Recent $600M senior note issuance improving capital structure
- Forward earnings guidance indicating rapid EPS expansion
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Exposure to emerging‑market regulatory and geopolitical risks
- Negative free cash flow and uncertain dividend sustainability
- Undervalued balance sheet metrics (price‑to‑book 0.008, high ROE) offering upside potential
Key Metrics & Analysis
Financial Health
Revenue Growth31.30%
Profit Margin24.91%
P/E Ratio7.8
ROE46.75%
ROA14.30%
Debt/Equity11.86
P/B Ratio0.0
Free Cash Flow$-736221528064
Industry P/E39.5
Technical Analysis
TrendBullish
RSI65.1
Support$83.55
Resistance$92.81
MA 20$87.61
MA 50$81.40
MA 200$79.86
MACDBullish
VolumeStable
Fear & Greed Index91.61
Valuation
Target Price$100.95
Upside/Downside10.28%
GradeUndervalued
TypeGrowth
Dividend Yield3.92%
Risk Assessment
Beta1.28
Volatility42.03%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.